





an Open Access Journal by MDPI

Endometrial Stem/Progenitor Cell Biology: Prospects and Challenges

Guest Editors:

Prof. Caroline E. Gargett

Hudson Institute of Medical Research, The Ritchie Centre, Clayton, Australia

Prof. Dharani Hapangama

Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool Women's Hospital, Crown Street, Liverpool L8 7SS, UK

Deadline for manuscript submissions:

closed (20 September 2021)

Message from the Guest Editors

Several types of endometrial stem/progenitor cells have been identified: endometrial mesenchymal stem cells, endometrial epithelial progenitor cells and side population cells comprising a heterogeneous population, predominantly endothelial cells.

This Special Issue aims to highlight the challenges in endometrial stem/progenitor cell research, the application of endometrial stem/progenitor cells as a cell-based therapy for treating disorders will be welcomed.

Areas to be covered in this Special Issue may include but are not limited to: recent evidence of cell-based therapies utilising endometrial derived mesenchymal stem cells, endometrial epithelial progenitors, topics including endometrial clonal evolution, mutation burden, 3D histoarchitecture, endometrial epithelial organoids and single cell sequencing which may have important relevance to endometrial stem/ progenitor cell biology and application in personalised medicine. Contributions by experts in the field, in the form of original research papers and reviews are most welcome













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University,

Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us